| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
Octacosanoic acid is an endogenous metabolite and a component of D-003, a mixture of very long-chain fatty acids. Its biological targets include pathways involved in platelet aggregation and cholesterol metabolism. As a fatty acid, it may interact with various lipid metabolism enzymes and receptors. The antiplatelet activity of D-003 suggests that octacosanoic acid may inhibit platelet aggregation through modulation of arachidonic acid metabolism or thromboxane production. Its cholesterol-lowering activity may involve inhibition of HMG-CoA reductase or enhancement of cholesterol excretion.
|
|---|---|
| ln Vitro |
In vitro, octacosanoic acid is a component of D-003, which has shown antiplatelet and cholesterol-lowering activities. As a very long-chain fatty acid, it may modulate lipid metabolism in cell culture systems. However, specific in vitro activity data for octacosanoic acid alone are limited, as most studies have focused on the D-003 mixture. The compound may affect platelet aggregation in vitro and reduce cholesterol synthesis in hepatic cell lines. Detailed IC50 values are not extensively reported.
|
| ln Vivo |
In vivo, octacosanoic acid is the major component of D-003, which has demonstrated antiplatelet and cholesterol-lowering activities in animal models. D-003 has been shown to reduce platelet aggregation and lower serum cholesterol levels in various animal species. Octacosanoic acid as a single compound is expected to contribute to these activities. However, specific in vivo efficacy data for octacosanoic acid alone are limited, as most studies have evaluated the D-003 mixture.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for octacosanoic acid as a drug target. As an endogenous metabolite, it may be studied in fatty acid metabolism assays. Typical assays would involve incubation of the compound with fatty acid-binding proteins, lipid metabolism enzymes (e.g., acyl-CoA synthetase), or assessment of its effects on platelet aggregation in vitro using platelet-rich plasma. However, detailed assay protocols are not extensively reported in the available literature for this specific compound.
|
| Cell Assay |
There are no specific in vitro cellular assays for octacosanoic acid as a pharmacologically active compound. As a fatty acid, it can be tested in hepatic cell lines (e.g., HepG2) to assess effects on lipid metabolism, cholesterol synthesis, and gene expression of lipid-regulating enzymes. Platelet aggregation assays using washed platelets or platelet-rich plasma can assess antiplatelet activity. However, detailed cellular assay protocols for this specific compound are not extensively reported in the available literature.
|
| Animal Protocol |
There are no specific in vivo animal studies for octacosanoic acid as a single compound. However, D-003 (which contains octacosanoic acid as a major component) has been studied in animal models. Typical studies involve oral administration of D-003 to rodents or rabbits at doses of 5-50 mg/kg daily for 2-4 weeks. Parameters assessed include serum lipid profile (total cholesterol, LDL, HDL, triglycerides), platelet aggregation, and bleeding time. Organ weights and histopathology are also evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of octacosanoic acid: As a very long-chain saturated fatty acid (C28), it is highly lipophilic and has poor aqueous solubility. Following oral administration, it is expected to be absorbed in the small intestine and incorporated into chylomicrons for transport in the lymphatic system. It is metabolized via β-oxidation in mitochondria and peroxisomes. The elimination half-life is likely long due to its lipophilic nature and extensive tissue distribution. Specific PK parameters are not extensively reported.
|
| Toxicity/Toxicokinetics |
The toxicity profile of octacosanoic acid is not extensively reported. As a naturally occurring fatty acid, it is expected to have low toxicity. The compound is for research use only and not for human therapeutic use. Standard toxicity studies would include acute oral toxicity in rodents and repeated-dose toxicity studies with monitoring of body weight, clinical signs, hematology, clinical chemistry, and histopathology. No specific genotoxicity or carcinogenicity data are reported.
|
| References | |
| Additional Infomation |
Octadecanic acid is a straight-chain saturated fatty acid formed when a terminal methyl group in the octacosane molecule is oxidized to the corresponding carboxyl group. It is a plant metabolite. It is both a straight-chain saturated fatty acid and an ultra-long-chain fatty acid. It is the conjugate acid of octacosane. Octadecanic acid has been reported to exist in gentian (Gentiana macrophylla), lysimachia patungensis, and other organisms with relevant data.
Octacosanoic acid (CAS 506-48-9) is a very long-chain saturated fatty acid that is the major component of D-003, a mixture of very long-chain aliphatic acids purified from sugar cane wax. D-003 has demonstrated antiplatelet and cholesterol-lowering activities in animal models, suggesting potential cardiovascular benefits. Octacosanoic acid is also used in industrial applications as a lubricant and in the preparation of flame-retardant and antibacterial materials. It is an endogenous metabolite and is available for research purposes only. |
| Molecular Formula |
C28H56O2
|
|---|---|
| Molecular Weight |
424.7430
|
| Exact Mass |
424.428
|
| CAS # |
506-48-9
|
| Related CAS # |
52258-47-6 (1/2Ca salt)
|
| PubChem CID |
10470
|
| Appearance |
White to light yellow solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
430.5±8.0 °C at 760 mmHg
|
| Melting Point |
91-93 °C(lit.)
|
| Flash Point |
192.5±13.3 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.462
|
| LogP |
13.53
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
30
|
| Complexity |
327
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UTOPWMOLSKOLTQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H56O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28(29)30/h2-27H2,1H3,(H,29,30)
|
| Chemical Name |
octacosanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :< 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3544 mL | 11.7719 mL | 23.5438 mL | |
| 5 mM | 0.4709 mL | 2.3544 mL | 4.7088 mL | |
| 10 mM | 0.2354 mL | 1.1772 mL | 2.3544 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
